Article Text

PDF

Neoplasia and cancer pathogenesis
Antisense immunochemogene therapy composed of sirna targeting vegf-a165b mRNA, antivegfmab and txt inhibited vegf mediated desmoplastic response, angiogenesis and lymphangiogenesis inducing maturation of DCS, ADCC, CMC, autophagy and PCD in PDAC
  1. J Giannios *
  1. Translational Cancer Medicine, Erasinio Oncology Hospital, Athens, Greece

Abstract

Introduction In pancreatic ductal adenocarcinoma, the desmoplastic response is predominant. VEGF-A165b causes resistance to bevacizumab.

Methods We established a clinically relevant model of PDAC in animals by orthotopically inoculating human PDAC cells overexpressing VEGF-A165b and bcl-2. We treat the PDAC models with siRNA VEGF-A165b, termed as SEVINA-VI. We co-administer docetaxel. As control, we used only bevacizumab.

Results Post-treatment, the RNAi induced by long dsRNA processed into 23 bp dsRNA by DICER has incorporated siRNA into RISC blocking VEGF-A165b mRNA. The formulation SEVINA-VI (under patent) allowed bevacizumab to inhibit VEGF-A blocking VEGFR-1, VEGFR2, angiogenesis and lymphangiogenesis reducing LYVE-1, Prox-1, podoplanin, 5-nucleotidase and LVD. Calcineurin and NFATc1 were blocked, inhibiting Csp1Ex4 and COX-2 and IL-1b. Inhibition of TAMs blocked production of MCP-1, IL-6 and RANTES. DC maturation produced IFN-γ inducing Th1, IL-2, CTL, cellular immunity, phosphorylation of STAT3, p38 and JNK. Also, DCs reduced CD1a/CD208 and with IKDC expressed S-100, CD83, CD86, CD80, Cd40, CCR7, and MHC-II inducing Teff, and Trg. In blood, there was enhancement of IL-1b, IL-6, IP-10, TNF-a and IL-12p70. Bevacizumab induced ADCC and CDC. Docetaxel phosphorylated bcl-2 at ser70 and released beclin1 in cytoplasm interacting with Vps34/Vps15. Autophagy or type II PCD was induced, where LC3II and ATG8 relocated to autophagosomes inhibiting PKCe, PI3K/AKT/mTOR and MAPK. Docetaxel by inhibiting bcl-2 blocks BAG1, TIMP3, AKT1, FAIM, BIM, PUMA, MEK/ERK, Mcl-1, NF-kB, FOXM1, TF and FVIIa circumventing Trousseau's syndrome, and inhibition of type I PCD activating caspase 3, 8, 9 and PARP cleavage after inhibition of JAK/STAT5. Bevacizumab's action was antagonised by VEGF-A165b in controls.

Conclusion AICT formulation composed of antiVEGF-A165b siRNA (SEVINA-VI), anti-VEGF Mab (bevacizumab), and docetaxel would be a novel strategy against PDAC.

  • PDAC
  • antisense immunochemogene therapy
  • siRNA
  • VEGF-A165b
  • PCD
  • trousseau's syndrome

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.